Wells Fargo & Company Issues Positive Forecast for Merit Medical Systems (NASDAQ:MMSI) Stock Price

Merit Medical Systems (NASDAQ:MMSI) had its target price hoisted by Wells Fargo & Company from $83.00 to $92.00 in a research report report published on Friday morning,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

MMSI has been the subject of a number of other reports. JPMorgan Chase & Co. raised their price target on Merit Medical Systems from $77.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Bank of America increased their target price on shares of Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Needham & Company LLC raised their target price on shares of Merit Medical Systems from $101.00 to $106.00 and gave the stock a “buy” rating in a report on Friday. Canaccord Genuity Group set a $121.00 price target on shares of Merit Medical Systems in a research note on Friday. Finally, Freedom Capital began coverage on shares of Merit Medical Systems in a report on Tuesday. They set a “hold” rating on the stock. Eight research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average target price of $105.55.

Merit Medical Systems Stock Down 7.7%

Shares of NASDAQ:MMSI opened at $86.24 on Friday. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems has a 12 month low of $59.74 and a 12 month high of $94.85. The company has a 50-day moving average price of $88.60 and a 200 day moving average price of $77.14. The company has a market cap of $5.15 billion, a price-to-earnings ratio of 32.42, a PEG ratio of 2.33 and a beta of 0.51.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.08. Merit Medical Systems had a return on equity of 14.37% and a net margin of 9.94%. The company had revenue of $416.24 million for the quarter, compared to analysts’ expectations of $410.56 million. During the same period in the previous year, the firm posted $0.92 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, equities research analysts predict that Merit Medical Systems will post 3.84 earnings per share for the current year.

Institutional Trading of Merit Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kilter Group LLC bought a new position in Merit Medical Systems during the 2nd quarter worth about $25,000. Salomon & Ludwin LLC raised its holdings in shares of Merit Medical Systems by 140.8% in the 3rd quarter. Salomon & Ludwin LLC now owns 537 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 314 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Merit Medical Systems by 88.6% in the 3rd quarter. IFP Advisors Inc now owns 694 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 326 shares in the last quarter. Harbor Investment Advisory LLC purchased a new stake in shares of Merit Medical Systems in the 2nd quarter worth approximately $50,000. Finally, Pinnacle Wealth Planning Services Inc. lifted its position in shares of Merit Medical Systems by 84.0% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 784 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 358 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q3 earnings beat expectations. Merit reported third-quarter revenue of $416.2 million, up 8.4% year over year and ahead of the $410.6 million consensus estimate. Non-GAAP EPS was $1.12 versus expectations of $1.04, while GAAP EPS rose 51% to $0.70. Merit Medical Q3 2026 results
• Positive Sentiment: Profitability and cash generation improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and year-to-date operating cash flow reached $175.2 million, with $129.5 million in free cash flow.
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 earnings outlook following the strong quarter, supporting expectations for continued growth. Merit Medical raises 2026 guidance
• Positive Sentiment: Analysts raised targets. BTIG Research lifted its target from $105 to $110 and maintained a buy rating. Wells Fargo raised its target from $83 to $92, although it retained an equal-weight rating. Analysts raise Merit Medical price targets
• Positive Sentiment: Cardiac-therapy capabilities expanded. Merit acquired Solo Pace, adding temporary pacing technology designed for patients with aortic stenosis and strengthening its TAVR-related product portfolio. Merit Medical acquires Solo Pace
• Neutral Sentiment: Valuation remains a consideration. With the stock trading at roughly 36 times earnings and near its 52-week high, investors may be demanding continued execution, leaving limited room for disappointment.
• Negative Sentiment: Some caution remains among analysts. Wells Fargo’s equal-weight rating and the company’s narrowed sales outlook temper the bullish impact of the earnings beat and guidance increase.

About Merit Medical Systems

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.